Birol YILDIZ

Dr. Birol YILDIZ

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 June 2021 in Cancer Investigation
Verified
Journal Article
Closed access
ABAykut Bahçeci
Aykut Bahçeci
SPSemra Paydas
Semra Paydas
NANaziye Ak
Naziye Ak
FFFerhat Ferhatoğlu
Ferhat Ferhatoğlu
PSPınar Mualla Saip
Pınar Mualla Saip
NYNilgün Yildirim
Nilgün Yildirim
The aim of this study is to evaluate the efficacy and toxicity of trastuzumab emtansine (T-DM1) in cases with metastatic breast cancer (mBC) in different lines of treatment.Retrospective analysis o...

24 June 2020 in Eurasian Journal of Medicine and Oncology
Verified
Journal Article
Closed access
PDF file
BYBirol YILDIZ
Birol YILDIZ
RARamazan Acar
Ramazan Acar
Objectives: Successful responses have been obtained in treating many solid and hematological cancers using PD-1 and PDL-1 inhibitors as immunotherapy treatments. Although cancer is more common in elderly patients, this group is generally not included in clinical trials. Therefore, studies involving geriatric patients cannot reflect real-life data. The aim of our study is to share the real-life data of patients aged 65 years and older who had different cancer diagnoses and received immunotherapy treatments. Methods: In our study, patients aged ≥65 years who received immunotherapy treatment at our center between 16.02.2016 and 31.12.2019 were evaluated retrospectively. The primary outcome was treatment tolerance and progression-free survival (PFS). The secondary outcomes were the overall survey immunotherapy (OSim). Results: The median age to start immunotherapy was 70 years (range 66–78). Comorbid diseases were present in 20 (74%) of the patients. The most common primary malignancy type was renal cell cancer (RCC) (n=9, 33.3%). The median PFS was 7.3 (range 1–49) months. After immunotherapy, 2 patients (7.4%) had complete response (CR), 13 patients (48.1%) partial response (PR), 5 patients (18.5%) stable response and 7 patients (25.9%) progression. The most common side effect was fatigue, occurring in 44.4% (n=12) of patients. Moreover, 66.7% (n=18) experienced an immunotherapyrelated adverse event (irAE), among which rash (21%), thyroid dysfunction (13%), and pneumonitis (12%) were the most common. None of the patients died due to treatment-related side effects. Conclusion: Although the efficacy of immunotherapy treatments was affected by comorbid diseases among cancer patients, it was observed that the elderly patients have efficacy and tolerability in accordance with the literature.

3 October 2025 in Current Oncology
Verified
Journal Article
Open access
PDF file
ASAtilla Soran
Atilla Soran
BGBerk Göktepe
Berk Göktepe
BDBerkay Demirors
Berkay Demirors
OAOzgur Aytac
Ozgur Aytac
SOSERDAR OZBAS
SERDAR OZBAS
ALAnthony Lucci
Anthony Lucci
Introduction: The impact of locoregional treatment (LRT) on survival in de novo bone-only metastatic breast cancer (dnBOMBC) is controversial. This study aims to assess the effect of LRT on survival, utilizing international, prospectively acquired data in this cohort of patients. Materials and Methods: Patients with dnBOMBC were divided into two groups: those receiving systemic therapy only (ST) and those undergoing LRT. Further, patients who received LRT were divided into two subgroups: those who received ST after LRT (LRT+ST group) and those who received ST prior to LRT (ST+LRT group). Factors associated with disease progression, including solitary or multiple bone metastases, were analyzed. Results: There was a total of 744 patients with dnBOMBC treated at each of the participating institutions between 2014 and 2022, with 372 (50%) participants in each arm. Median follow-up was 48 months (32–66, 25–75%). Patients in the LRT group were significantly younger than the ST group [50 (42, 60) vs. 55 (44, 66), p = 0.0001]. There were no significant differences in grade, HER2 status, triple-negative status, receipt of hormonal therapy, or intervention to metastatic sites. During follow-up, 58% (n = 217) of patients in the ST group and 32% (n = 120) of patients in the LRT group died (p < 0.001). Local progression was observed in 20% of the patients in the ST group, whereas 9% progressed in the LRT group (p = 0.0001). Systemic progression occurred more in the ST group; 66% (n = 244) compared to 41% (n = 152) of patients in the LRT group (p < 0.001). The hazard of death was 64% lower in the LRT group than in the ST group (HR: 0.36, 95% CI: 0.29–0.45, p < 0.0001). The burden of metastatic disease differed significantly between the two groups, with a higher rate of solitary bone metastases in the LRT group compared to the ST group (50% vs. 24%, p < 0.001). However, the LRT group had better overall survival (OS) for both solitary (HR: 0.38, 95% Cl: 0.26–0.55) and multiple (HR: 0.38, 95% Cl: 0.29–0.51) bone metastasis patients. Within the LRT group, survival rates were similar whether the breast surgery was performed before or after ST. Multivariate Cox analysis showed that LRT and ER/PR positivity significantly decrease the hazard of death (p < 0.05). Conclusions: Analysis of this large multi-institutional patient cohort provides further evidence that LRT is associated with longer OS and lower locoregional recurrence rates in patients with dnBOMBC. In breast cancer patients with bone-only metastases at presentation, the decision for LRT should be made through a multidisciplinary approach with consideration of surgical therapy at the primary tumor.

1 March 2021 in Leukemia Research
Verified
Journal Article
Closed access
SPSemra Paydas
Semra Paydas
SLSahin Lacin
Sahin Lacin
MDMutlu Dogan
Mutlu Dogan
Ibrahim BaristaIbrahim Barista
Ibrahim Barista
BYBirol YILDIZ
Birol YILDIZ
VEVehbi Ercolak
Vehbi Ercolak

1 December 2023 in Medical Science and Discovery
Verified
Journal Article
Open access
PDF file
TDTolga Doğan
Tolga Doğan
ITIlker Tasci
Ilker Tasci
UBUğur Bozlar
Uğur Bozlar
BYBirol YILDIZ
Birol YILDIZ
CACengizhan Acikel
Cengizhan Acikel
KSKenan Sağlam
Kenan Sağlam
Objective: This study aims to assess the sensitivity and specificity of ankle-brachial index (ABI) measurements in diagnosing peripheral artery disease (PAD) among a cohort of Turkish subjects, with angiography serving as the reference standard. Material and Methods: In this single-center, cross-sectional and observational study, subjects who had an aorta and lower extremity arterial imaging by angiography subsequently underwent an ABI measurement. Anthropometric measurements, cardiovascular risk factors, and blood biochemistry data were recorded. Sensitivity and specificity analyses were performed for a low ankle-brachial index (ABI ≤ 0.9), with angiography as the reference standard. Results: A total of 57 patients (age: 59.1±15.9, male/female: 47/10) were included. Diabetes mellitus, coronary artery disease and cerebrovascular disease were present in 40.4%, 42.1% and 15.8% of the participants, respectively. Three or more cardiovascular risk factors were present in 54.4%. The angiographic diagnostic method was computed tomography angiography in 57.9%, digital subtraction angiography in 38.6%, and magnetic resonance angiography in 3.5% of the subjects. The presence of PAD on angiography was documented in 55 of 57 participants. The calculated mean ABI value was 0.6±0.2 in the overall group, and a low ABI (≤0.9) was found by 82.5% (n = 47). Compared to angiography, the low ankle-brachial index (ABI) test demonstrated a sensitivity of 83.6% and a specificity of 50%. The positive predictive value of 97.9% was calculated. When an ABI≤0.95 was used as the diagnostic threshold, the sensitivity of the ABI test increased to 90.9%. Conclusion: Our study confirms the reliability of ABI measurements as a diagnostic method for lower extremity peripheral artery disease (PAD) when compared to angiographic techniques, the gold standard. Establishing a higher cut-off value (≤0.95) may enhance the diagnostic performance of the test in Turkish patients.

28 August 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
ASAtilla Soran
Atilla Soran
BGBerk Göktepe
Berk Göktepe
BDBerkay Demirors
Berkay Demirors
OAOzgur Aytac
Ozgur Aytac
SOSERDAR OZBAS
SERDAR OZBAS
ALAnthony Lucci
Anthony Lucci
Introduction: The impact of loco-regional treatment (LRT) on survival in de novo bone-only metastatic breast cancer (dnBOMBC) is controversial. The aim of this study is to assess the effect of LRT on survival utilizing international, prospectively acquired data in this cohort of patients. Materials and Methods: Patients with dnBOMBC were divided into two groups: those receiving systemic therapy only (ST) and those undergoing LRT. Further, patients who received LRT were divided into two subgroups: those who received ST after LRT (LRT+ST group) and those who received ST prior to LRT (ST+LRT group). Factors associated with disease progression including solitary or multiple bone metastases were analyzed. Results: There was a total of 744 patients with dnBOMBC treated at each of the participating institutions between 2014 and 2022, with 372 (50%) participants in each arm. Median follow-up was 48 months (32-66, 25-75%). Patients in the LRT group were significantly younger than the ST group [50 (42, 60) vs. 55 (44, 66), p=0.0001]. There were no significant differences in grade, HER2 status, triple-negative status, receipt of hormonal therapy, or intervention to metastatic sites. During follow-up, 58% (n=217) of patients in ST group and 32% (n=120) of patients in LRT group died (p<0.001). Local progression was observed in 20% of the patients in the ST group, whereas 9% progressed in the LRT group (p=0.0001). Systemic progression occurred more in the ST group; 66% (n=244) compared to 41% (n=152) of patients in the LRT group (p<0.001). The Hazard of death was 64% lower in LRT group than in ST group (HR: 0.36, 95% CI: 0.29-0.45, p<0.0001). The burden of metastatic disease differed significantly between the two groups with a higher rate of solitary bone metastases in the LRT group compared to the ST group (50% vs. 24%, p<0.001). However, the LRT group had better overall survival (OS) for both solitary (HR: 0.38, 95% Cl: 0.26-0.55) and multiple (HR: 0.38, 95% Cl: 0.29-0.51) bone metastases patients. Within the LRT group, survival rates were similar whether the breast surgery was performed before or after ST. Multivariate Cox analysis showed that LRT and ER/PR positivity significantly decrease the hazard of death (p<0.05). Conclusion: Analysis of this large multi-institutional patient cohort provides further evidence that LRT improves OS and lowers loco-regional recurrence in patients with dnBOMBC. In breast cancer patients with bone-only metastases at presentation, the decision for LRT should be made through a multidisciplinary approach with consideration of surgical therapy at the primary tumor.